This study demonstrates that, apparently, there is no distinctive feature of DHL/THL lymphoma with respect to sensitivity to BET inhibitors, and MYC-expressing lymphoma cells are probably addicted to the MYC-oncogenic effect and rely on MYC for their growth regardless of MYC rearrangements. The gene discussed is MYC; the disease is lymphoma.